Evidence map›Paper›PMID 36090617›Full record

ArticleEuropean journal of radiology open2022

Feasibility of using CT radiomic signatures for predicting CD8-T cell infiltration and PD-L1 expression in renal cell carcinoma.

Bino Varghese, Steven Cen, Haris Zahoor, Imran Siddiqui, Manju Aron, Akash Sali, Suhn Rhie, Xiaomeng Lei, Marielena Rivas, Derek Liu and 6 more

Open access · goldAbstract read
In one paragraph

Article in European journal of radiology open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Review
  8. The potential value of dual-energy CT radiomics in evaluating CD8Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Bino VargheseUSC Radiomics Laboratory, Keck School of Medicine, Department of Radiology, University of Southern California, Los Angeles, CA, USA.
Steven CenUSC Radiomics Laboratory, Keck School of Medicine, Department of Radiology, University of Southern California, Los Angeles, CA, USA.
Haris ZahoorKeck School of Medicine, Department of Medicine, University of Southern California, Los Angeles, CA, USA.
Imran SiddiquiKeck School of Medicine, Department of Pathology, University of Southern California, Los Angeles, CA, USA.
Manju AronKeck School of Medicine, Department of Pathology, University of Southern California, Los Angeles, CA, USA.
Akash SaliHomi Bhabha Cancer Hospital, Department of Pathology, Sangrur, Punjab, India.
Suhn RhieKeck School of Medicine, Department of Molecular Medicine, University of Southern California, Los Angeles, CA, USA.
Xiaomeng LeiUSC Radiomics Laboratory, Keck School of Medicine, Department of Radiology, University of Southern California, Los Angeles, CA, USA.
Marielena RivasUSC Radiomics Laboratory, Keck School of Medicine, Department of Radiology, University of Southern California, Los Angeles, CA, USA.
Derek LiuUSC Radiomics Laboratory, Keck School of Medicine, Department of Radiology, University of Southern California, Los Angeles, CA, USA.
Darryl HwangUSC Radiomics Laboratory, Keck School of Medicine, Department of Radiology, University of Southern California, Los Angeles, CA, USA.
David QuinnKeck School of Medicine, Department of Medicine, University of Southern California, Los Angeles, CA, USA.
Mihir DesaiKeck School of Medicine, Department of Urology, University of Southern California, Los Angeles, CA, USA.
Ulka VaishampayanRogel Cancer Center, Urologic Oncology Clinic, University of Michigan, Ann Arbor, MI, USA.
Inderbir GillKeck School of Medicine, Department of Urology, University of Southern California, Los Angeles, CA, USA.
Vinay DuddalwarUSC Radiomics Laboratory, Keck School of Medicine, Department of Radiology, University of Southern California, Los Angeles, CA, USA.
University of Southern California · USBhabha Hospital · INUniversity of Michigan–Ann Arbor · US

Funding

Southern California Clinical and Translational Science InstituteUL1TR001855 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Thomas A Buchanan, Michele D. Kipke · 2016 to 2026
$81.3M
Identification and Clinical Validation of Key Transcription Factor Isoforms Linked to Breast and Prostate Cancer Subgroups using Epigenetic TraitsK01CA229995 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RHIE, SUHN KYONG · 2018 to 2020
$637k
Identifying epigenetic states of TADs and targeting using epigenome editingR21HG011506 · NHGRI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RHIE, SUHN KYONG · 2021 to 2023
$619k
Mapping regulatory elements and chromatin structures in prostate tumor subtypes at single nucleosome resolutionR21CA264637 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RHIE, SUHN KYONG · 2021 to 2022
$420k
Reversing molecular cancer phenotypes by targeting epigenetic alterations in prostate cancerR21CA260082 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RHIE, SUHN KYONG · 2021 to 2021
$386k
NCATS NIH HHS UL1 TR001855NCI NIH HHS K01 CA229995NCI NIH HHS R21 CA260082NHGRI NIH HHS R21 HG011506
6 · The paper itself

Abstract

Objectives: To identify computed tomography (CT)-based radiomic signatures of cluster of differentiation 8 (CD8)-T cell infiltration and programmed cell death ligand 1 (PD-L1) expression levels in patients with clear-cell renal cell carcinoma (ccRCC). Methods: Seventy-eight patients with pathologically confirmed localized ccRCC, preoperative multiphase CT and tumor resection specimens were enrolled in this retrospective study. Regions of interest (ROI) of the ccRCC volume were manually segmented from the CT images and processed using a radiomics panel comprising of 1708 metrics. The extracted metrics were used as inputs to three machine learning classifiers: Random Forest, AdaBoost, and ElasticNet to create radiomic signatures for CD8-T cell infiltration and PD-L1 expression, respectively. Results: Using a cut-off of 80 lymphocytes per high power field, 59 % were classified to CD8 highly infiltrated tumors and 41 % were CD8 non highly infiltrated tumors, respectively. An ElasticNet classifier discriminated between these two groups of CD8-T cells with an AUC of 0.68 (95 % CI, 0.55-0.80). In addition, based on tumor proportion score with a cut-off of > 1 % tumor cells expressing PD-L1, 76 % were PD-L1 positive and 24 % were PD-L1 negative. An Adaboost classifier discriminated between PD-L1 positive and PD-L1 negative tumors with an AUC of 0.8 95 % CI: (0.66, 0.95). 3D radiomics metrics of graylevel co-occurrence matrix (GLCM) and graylevel run-length matrix (GLRLM) metrics drove the performance for CD8-Tcell and PD-L1 classification, respectively. Conclusions: CT-radiomic signatures can differentiate tumors with high CD8-T cell infiltration with moderate accuracy and positive PD-L1 expression with good accuracy in ccRCC.

Indexed as

CD8-Positive T-Lymphocytes/immunologyImage Processing, Computer-AssistedImaging, Three-DimensionalKidney Neoplasms/pathologyProgrammed Cell Death 1 Receptor/immunology

Identifiers

PMID36090617
PMCPMC9460152
OpenAlexW4294266034

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.